Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma

Tomoyuki Tano, Masato Okamoto, Shin Kan, Koh Ichi Nakashiro, Shigetaka Shimodaira, Shigeo Koido, Sadamu Homma, Mitsunobu Sato, Tomonobu Fujita, Yutaka Kawakami, Hiroyuki Hamakawa

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Antitumor functions of the host immune system are frequently compromised in patients with malignancies. In the current study, we evaluated the relationship between expression ratio of mRNAs for the antiapoptotic protein Bcl-2 and the proapoptotic protein Bax (the Bcl-2/Bax ratio) in peripheral blood mononuclear cells and clinical outcomes in patients with head and neck carcinomas. The overall survival (OS) time of patients with Bcl-2/Bax ratios ≥ 1.2 tended to be longer than that of patients with Bcl-2/Bax ratios < 1.2 but not significantly so (P =.084, n = 61). Disease-free survival (DFS) of patients with Bcl-2/Bax ratios ≥ 1.2 was statistically significantly longer than that of patients with Bcl-2/Bax ratios < 1.2 (P =.001, n = 76). All of the patients whose Bcl-2/Bax ratio is ≥ 2.0 were alive after 36 months and survived without any evidence of disease for 24 months (Bcl-2/Bax ≥ 2.0 versus Bcl-2/Bax < 2.0; P =.035, n = 61 in OS, P <.001, n = 76 in DFS, respectively). In 56 patients who received immunochemoradiotherapy using UFT and OK-432 in combination with radiotherapy, a statistically significant relationship between the Bcl-2/Bax ratio and the therapeutic effect estimated using Response Evaluation Criteria in Solid Tumors was observed, as well as a relation with interferon-γ (IFN-γ) induction in response to the therapy [P =.002 in complete response versus partial response + stable disease; P =.046 in IFN-γ(+) versus IFN-γ(-)]. In addition, there were significant correlations of the Bcl-2/Bax ratio with both the absolute number of CD4+ T cells and the rate of CD4+ T cell and natural killer cell activity. These findings strongly suggest that the balance of expression of Bcl-2 and Bax genes in circulating immune cells has a high prognostic value in head and neck cancer patients.

Original languageEnglish
Pages (from-to)305-314
Number of pages10
JournalNeoplasia (United States)
Volume15
Issue number3
DOIs
Publication statusPublished - 2013

Fingerprint

bcl-2 Genes
Neck
Head
Carcinoma
Interferons
Disease-Free Survival
Picibanil
T-Lymphocytes
bcl-2-Associated X Protein
Survival
Therapeutic Uses
Head and Neck Neoplasms
Natural Killer Cells
Immune System
Blood Cells
Radiotherapy
Messenger RNA

ASJC Scopus subject areas

  • Cancer Research

Cite this

Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma. / Tano, Tomoyuki; Okamoto, Masato; Kan, Shin; Nakashiro, Koh Ichi; Shimodaira, Shigetaka; Koido, Shigeo; Homma, Sadamu; Sato, Mitsunobu; Fujita, Tomonobu; Kawakami, Yutaka; Hamakawa, Hiroyuki.

In: Neoplasia (United States), Vol. 15, No. 3, 2013, p. 305-314.

Research output: Contribution to journalArticle

Tano, T, Okamoto, M, Kan, S, Nakashiro, KI, Shimodaira, S, Koido, S, Homma, S, Sato, M, Fujita, T, Kawakami, Y & Hamakawa, H 2013, 'Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma', Neoplasia (United States), vol. 15, no. 3, pp. 305-314. https://doi.org/10.1593/neo.121528
Tano, Tomoyuki ; Okamoto, Masato ; Kan, Shin ; Nakashiro, Koh Ichi ; Shimodaira, Shigetaka ; Koido, Shigeo ; Homma, Sadamu ; Sato, Mitsunobu ; Fujita, Tomonobu ; Kawakami, Yutaka ; Hamakawa, Hiroyuki. / Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma. In: Neoplasia (United States). 2013 ; Vol. 15, No. 3. pp. 305-314.
@article{46b70d7d3315484cae8a9b645fb7f3a1,
title = "Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma",
abstract = "Antitumor functions of the host immune system are frequently compromised in patients with malignancies. In the current study, we evaluated the relationship between expression ratio of mRNAs for the antiapoptotic protein Bcl-2 and the proapoptotic protein Bax (the Bcl-2/Bax ratio) in peripheral blood mononuclear cells and clinical outcomes in patients with head and neck carcinomas. The overall survival (OS) time of patients with Bcl-2/Bax ratios ≥ 1.2 tended to be longer than that of patients with Bcl-2/Bax ratios < 1.2 but not significantly so (P =.084, n = 61). Disease-free survival (DFS) of patients with Bcl-2/Bax ratios ≥ 1.2 was statistically significantly longer than that of patients with Bcl-2/Bax ratios < 1.2 (P =.001, n = 76). All of the patients whose Bcl-2/Bax ratio is ≥ 2.0 were alive after 36 months and survived without any evidence of disease for 24 months (Bcl-2/Bax ≥ 2.0 versus Bcl-2/Bax < 2.0; P =.035, n = 61 in OS, P <.001, n = 76 in DFS, respectively). In 56 patients who received immunochemoradiotherapy using UFT and OK-432 in combination with radiotherapy, a statistically significant relationship between the Bcl-2/Bax ratio and the therapeutic effect estimated using Response Evaluation Criteria in Solid Tumors was observed, as well as a relation with interferon-γ (IFN-γ) induction in response to the therapy [P =.002 in complete response versus partial response + stable disease; P =.046 in IFN-γ(+) versus IFN-γ(-)]. In addition, there were significant correlations of the Bcl-2/Bax ratio with both the absolute number of CD4+ T cells and the rate of CD4+ T cell and natural killer cell activity. These findings strongly suggest that the balance of expression of Bcl-2 and Bax genes in circulating immune cells has a high prognostic value in head and neck cancer patients.",
author = "Tomoyuki Tano and Masato Okamoto and Shin Kan and Nakashiro, {Koh Ichi} and Shigetaka Shimodaira and Shigeo Koido and Sadamu Homma and Mitsunobu Sato and Tomonobu Fujita and Yutaka Kawakami and Hiroyuki Hamakawa",
year = "2013",
doi = "10.1593/neo.121528",
language = "English",
volume = "15",
pages = "305--314",
journal = "Neoplasia (United States)",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma

AU - Tano, Tomoyuki

AU - Okamoto, Masato

AU - Kan, Shin

AU - Nakashiro, Koh Ichi

AU - Shimodaira, Shigetaka

AU - Koido, Shigeo

AU - Homma, Sadamu

AU - Sato, Mitsunobu

AU - Fujita, Tomonobu

AU - Kawakami, Yutaka

AU - Hamakawa, Hiroyuki

PY - 2013

Y1 - 2013

N2 - Antitumor functions of the host immune system are frequently compromised in patients with malignancies. In the current study, we evaluated the relationship between expression ratio of mRNAs for the antiapoptotic protein Bcl-2 and the proapoptotic protein Bax (the Bcl-2/Bax ratio) in peripheral blood mononuclear cells and clinical outcomes in patients with head and neck carcinomas. The overall survival (OS) time of patients with Bcl-2/Bax ratios ≥ 1.2 tended to be longer than that of patients with Bcl-2/Bax ratios < 1.2 but not significantly so (P =.084, n = 61). Disease-free survival (DFS) of patients with Bcl-2/Bax ratios ≥ 1.2 was statistically significantly longer than that of patients with Bcl-2/Bax ratios < 1.2 (P =.001, n = 76). All of the patients whose Bcl-2/Bax ratio is ≥ 2.0 were alive after 36 months and survived without any evidence of disease for 24 months (Bcl-2/Bax ≥ 2.0 versus Bcl-2/Bax < 2.0; P =.035, n = 61 in OS, P <.001, n = 76 in DFS, respectively). In 56 patients who received immunochemoradiotherapy using UFT and OK-432 in combination with radiotherapy, a statistically significant relationship between the Bcl-2/Bax ratio and the therapeutic effect estimated using Response Evaluation Criteria in Solid Tumors was observed, as well as a relation with interferon-γ (IFN-γ) induction in response to the therapy [P =.002 in complete response versus partial response + stable disease; P =.046 in IFN-γ(+) versus IFN-γ(-)]. In addition, there were significant correlations of the Bcl-2/Bax ratio with both the absolute number of CD4+ T cells and the rate of CD4+ T cell and natural killer cell activity. These findings strongly suggest that the balance of expression of Bcl-2 and Bax genes in circulating immune cells has a high prognostic value in head and neck cancer patients.

AB - Antitumor functions of the host immune system are frequently compromised in patients with malignancies. In the current study, we evaluated the relationship between expression ratio of mRNAs for the antiapoptotic protein Bcl-2 and the proapoptotic protein Bax (the Bcl-2/Bax ratio) in peripheral blood mononuclear cells and clinical outcomes in patients with head and neck carcinomas. The overall survival (OS) time of patients with Bcl-2/Bax ratios ≥ 1.2 tended to be longer than that of patients with Bcl-2/Bax ratios < 1.2 but not significantly so (P =.084, n = 61). Disease-free survival (DFS) of patients with Bcl-2/Bax ratios ≥ 1.2 was statistically significantly longer than that of patients with Bcl-2/Bax ratios < 1.2 (P =.001, n = 76). All of the patients whose Bcl-2/Bax ratio is ≥ 2.0 were alive after 36 months and survived without any evidence of disease for 24 months (Bcl-2/Bax ≥ 2.0 versus Bcl-2/Bax < 2.0; P =.035, n = 61 in OS, P <.001, n = 76 in DFS, respectively). In 56 patients who received immunochemoradiotherapy using UFT and OK-432 in combination with radiotherapy, a statistically significant relationship between the Bcl-2/Bax ratio and the therapeutic effect estimated using Response Evaluation Criteria in Solid Tumors was observed, as well as a relation with interferon-γ (IFN-γ) induction in response to the therapy [P =.002 in complete response versus partial response + stable disease; P =.046 in IFN-γ(+) versus IFN-γ(-)]. In addition, there were significant correlations of the Bcl-2/Bax ratio with both the absolute number of CD4+ T cells and the rate of CD4+ T cell and natural killer cell activity. These findings strongly suggest that the balance of expression of Bcl-2 and Bax genes in circulating immune cells has a high prognostic value in head and neck cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84874615958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874615958&partnerID=8YFLogxK

U2 - 10.1593/neo.121528

DO - 10.1593/neo.121528

M3 - Article

VL - 15

SP - 305

EP - 314

JO - Neoplasia (United States)

JF - Neoplasia (United States)

SN - 1522-8002

IS - 3

ER -